22.75

0.44% -0.0923

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $22.75, with a volume of 161.62K. It is down -0.44% in the last 24 hours and down -4.93% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Previous Close:

$22.84

Open:

$22.85

24h Volume:

161.62K

Relative Volume:

0.12

Market Cap:

$1.73B

Revenue:

$314.00K

Net Income/Loss:

$-237.73M

P/E Ratio:

-4.671

EPS:

-4.87

Net Cash Flow:

$-185.07M

1W Performance:

+0.00%

1M Performance:

-4.93%

6M Performance:

+47.66%

1Y Performance:

+49.70%

1-Day Range:

$22.31

$22.95

1-Week Range:

$21.53

$22.99

52-Week Range:

$11.40

$25.39

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

VRDN's Discussions on Twitter

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

02:36 AM

(VRDN) Long Term Investment Analysis - Stock Traders Daily

02:36 AM

Oct 31, 2024

Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance

Oct 31, 2024

Oct 28, 2024

Analyst Expectations For Viridian Therapeutics's Future - Fidelity Investments

Oct 28, 2024

Needham & Company LLC Reaffirms Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat

Oct 28, 2024

Oct 27, 2024

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Novo Holdings A S - MarketBeat

Oct 27, 2024

Oct 25, 2024

How To Trade (VRDN) - Stock Traders Daily

Oct 25, 2024

Oct 23, 2024

VRDN Factor-Based Stock Analysis - Nasdaq

Oct 23, 2024

Viridian Therapeutics' Superior Prospects Make It A Buy (NASDAQ:VRDN) - Seeking Alpha

Oct 23, 2024

Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results - Insider Monkey

Oct 23, 2024

Oct 22, 2024

8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Oct 22, 2024

Oct 21, 2024

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 21, 2024

Oct 19, 2024

SG Americas Securities LLC Has $374,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat

Oct 19, 2024

Oct 18, 2024

State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance

Oct 18, 2024

Viridian Therapeutics (NASDAQ:VRDN) Hits New 52-Week HighTime to Buy? - MarketBeat

Oct 18, 2024

Oct 16, 2024